Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17262434 | 0.98 | MGMT (0.40) | MGMTMGLLABCG2 | |
| SCHEMBL30455579 | 0.86 | MGMT (0.39) | MGMTMGLLABCG2 | |
| SCHEMBL30459733 | 0.86 | MGMT (0.39) | MGMTMGLLABCG2 | |
| SCHEMBL26349182 | 0.86 | MGMT (0.39) | MGMTMGLLABCG2 | |
| SCHEMBL18212282 | 0.82 | MGMT (0.40) | MGMTMGLLABCG2 | |
| SCHEMBL26349179 | 0.80 | MGMT (0.42) | MGMTMGLLABCG2 | |
| SCHEMBL26349189 | 0.80 | MGMT (0.42) | MGMTMGLL | |
| SCHEMBL30458078 | 0.80 | MGMT (0.42) | MGMTMGLLABCG2 | |
| SCHEMBL29199650 | 0.80 | HPGD (0.49) | MGMT | |
| SCHEMBL25495610 | 0.79 | MGLL (0.67) | MGMTMGLLABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117915956-A | M6PR cell surface receptor binding compounds and conjugates | 利西亚治疗公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-4087584-A2 | CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | MGMT 2296/4885MGLL 883/4885ABCG2 675/4885 |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | MGMT 4124/4885MGLL 508/4885ABCG2 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.